pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,098 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1173Endpoints890BioPharma Dive342BioSpace307Fierce Biotech290onclive165raps104globenewswire health73
therapy area
allOncology7582Rare Disease1868Cardiology1741Immunology1478Hematology1319Vaccines1197Pulmonology
  • Genentech shuts infectious disease research unit and lays off senior scientists in latest R&D cuts
    Genentech announced another round of layoffs affecting its early research and development group. The cuts included the closure of its infectious disease research unit and the departure of several…
    Endpoints · 2mo agoLayoffsNegative↗ source
  • Camurus receives second complete response letter for acromegaly drug CAM2029; Teva announces workforce reductions
    Camurus reported that the FDA issued a second complete response letter for its investigational acromegaly therapy CAM2029, citing issues related to a third‑party manufacturer. The agency’s concern…
    Endpoints · 2mo agoCRLNegative↗ source
← prev
page 60 of 84
next →
fda recalls69
fda medwatch60
fda press38
1171
Psychiatry & CNS866
Ophthalmology495
Pain480
Endocrinology & Metabolism473
Infectious Disease444
  • Neion Bio secures $23M Series A to develop egg-based protein platform for biologics
    Neion Bio announced it closed a $23 million Series A round that was oversubscribed. The funding will be used to advance its platform that leverages chicken eggs, extracting primordial germ cells f…
    Endpoints · 2mo agoDealPositive↗ source
  • Sensorion drops OTOF gene therapy to focus on GJB2-targeted hearing loss candidate after Regeneron approval
    Sensorion said it is ending development of its gene therapy SENS-501 for OTOF related hearing loss after a strategic review. The review concluded that the competitive landscape had changed signific…
    BioPharma Dive · 2mo agoNeutral↗ source
  • Sensorion halts development of SENS-501 for OTOF-related hearing loss after strategic review
    Sensorion announced it is ending the development of its SENS-501 candidate, which was aimed at treating OTOF-related hearing loss, following a strategic review of its pipeline. The biotech said it…
    Endpoints · 2mo agoNeutral↗ source
  • Biopharma’s top scientists and doctors earned eight-figure pay in 2025, still far below CEO salaries
    Endpoints News released a compensation report that ranks the ten highest-paid scientists and doctors in biopharma for 2025. The list shows that several executives received eight-figure total compe…
    Endpoints · 2mo agoNeutral↗ source
  • Parabilis Medicines raises $670 million in record-setting biotech IPO on Nasdaq
    Parabilis Medicines, a Cambridge, Massachusetts drug developer, completed its initial public offering on Nasdaq, raising $670 million. The offering is described as the largest biotech IPO in indus…
    Endpoints · 3mo agoDealPositive↗ source
  • AstraZeneca advances obesity pill to Phase 3 after mid-stage trials show ~11% weight loss
    AstraZeneca announced that its experimental oral GLP-1 drug, elecoglipron, will enter an extensive Phase 3 development program following encouraging data from two mid-stage studies in obesity and d…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • Parabilis raises $670M in record-setting Nasdaq debut to fund cancer drug development
    Parabilis completed a $670 million initial public offering on the Nasdaq, establishing the largest biotech debut in the exchange’s history. The offering drew strong investor demand even as attenti…
    Endpoints · 3mo agoDealPositive↗ source
  • Parabilis raises record $670 million in biotech IPO, the largest for a venture-backed company
    Parabilis Medicines, a biotech focused on "undruggable" targets, completed an initial public offering that raised $670 million, the biggest amount ever for a venture-backed biotech. The company so…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Sanofi halts Phase 3 trial of riliprubart in CIDP after interim analysis shows unlikely efficacy
    Sanofi announced Wednesday that it is stopping the Phase 3 MOBILIZE study of its experimental anti‑inflammatory drug riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (…
    BioPharma Dive · 3mo agoNegative readoutNegative↗ source
  • Beren Therapeutics secures $300 million to fund rare disease drug launch ahead of FDA review
    Beren Therapeutics announced it has raised $300 million in new financing to support the development and launch of its rare disease therapy. The funding arrives as the company prepares for an FDA d…
    Endpoints · 3mo agoDealPositive↗ source
  • Ethyreal Bio raises $101M to develop antibody targeting Graves disease and thyroid eye disease
    Ethyreal Bio, a Cambridge-based biotech that has just emerged from stealth mode, announced it has closed a $101 million financing round to advance its lead candidate. The company’s candidate, a mo…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Novartis inks second molecular glue partnership with Orionis, $40M upfront
    Novartis has entered a second agreement with Orionis Biosciences focused on molecular glue technology. The deal includes an upfront payment of $40 million. The agreement also provides for mileston…
    Endpoints · 3mo agoDealPositive↗ source
  • SonoThera secures $125 million to advance ultrasound-based gene therapy for Duchenne and polycystic kidney disease
    SonoThera announced it has raised $125 million in financing to move its ultrasound-based non-viral gene therapy platform toward clinical testing. The funding will support the company’s two lead pr…
    Endpoints · 3mo agoDealPositive↗ source
  • Shattuck Labs raises $75M in public offering, selling 10.5M shares at $4 each
    Shattuck Labs announced a $75 million public offering to raise capital. The company is selling more than 10.5 million shares at $4 per share and is also issuing pre‑funded warrants to selected inv…
    Endpoints · 3mo agoDealNeutral↗ source
  • Biotech executives pocket nearly $1 billion in M&A golden parachutes, 12 receive $35M+ payouts
    An Endpoints News analysis identified a group of twelve biotech leaders who collectively earned close to $1 billion in exit compensation after selling their companies. Each of these executives sec…
    Endpoints · 3mo agoNegative↗ source
  • Ethyreal Bio secures $101M to develop treatments for Graves' disease and thyroid eye disease
    Ethyreal Bio, a newly unveiled biotech, announced it has raised $101 million in financing. The round was led by venture firms Atlas Venture and Medicxi. The capital will be used to advance therape…
    Endpoints · 3mo agoDealPositive↗ source
  • Sanofi halts Phase 3 trial of riliprubart in rare neurological disorder
    Sanofi announced it is ending the Phase 3 study of its antibody drug riliprubart aimed at treating a rare neurological disease. The decision follows a recommendation from an independent data monit…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • GSK to buy Nuvalent for $10.6B, gaining two lung-cancer drugs under FDA review
    GSK announced it will acquire Nuvalent, a biotech focused on lung cancer, in a transaction valued at about $10.6 billion. The deal gives GSK control of Nuvalent’s two experimental lung-cancer ther…
    Endpoints · 3mo agoDealPositive↗ source
  • GSK to acquire Nuvalent for $11 billion, adding two lung-cancer drugs under FDA review
    GSK announced a deal to buy Massachusetts‑based biotech Nuvalent for $11 billion. The acquisition brings two experimental lung‑cancer medicines that are currently under review by the U.S. Food and…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Grace Science warns FDA bottleneck threatens ultra-rare gene therapy progress
    Grace Science, a biotech focused on ultra-rare diseases, has been developing a gene-therapy candidate that appeared close to regulatory approval. The company, co-founded by Nobel laureate Carolyn…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Garner Health secures $100 million funding, valuation climbs to $2.7 billion
    Garner Health announced a $100 million financing round that pushes its post‑money valuation to $2.7 billion. The capital raise was completed last month and was led by a group of venture investors.…
    Endpoints · 3mo agoDealPositive↗ source
  • Stealthy biotech Treeline Biosciences to go public via reverse merger with Standard BioTools
    Treeline Biosciences announced a plan to become a public company through a reverse merger with microfluidics firm Standard BioTools. The transaction will give Standard shareholders about 15.5% of…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Lilly proposes up to $1 billion for Alzheimer’s candidate, while Bial drops Parkinson’s program
    On June 9, 2026, Eli Lilly announced a potential licensing agreement for an Alzheimer’s disease candidate, offering an upfront payment of $10 million and the possibility of more than $1 billion bas…
    Endpoints · 3mo agoDealNeutral↗ source